ShockWave Medical, Inc. SWAV · Stock Open ShockWave Medical, Inc. in new tab
ShockWave Medical, Inc. Analysis (SWAV)
Is ShockWave Medical, Inc. a good investment? ShockWave Medical, Inc. (SWAV) is currently trading at 334.75 USD. Market analysts have a consensus price target of 316.14 USD. This suggests the asset is currently trading above analyst expectations.
In terms of valuation, the stock trades at a P/E ratio of 85.25. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: ShockWave Medical, Inc. is expected to release its next earnings report on May 6, 2024. The market consensus estimate for Forward EPS is 6.18.
Investor FAQ
Does ShockWave Medical, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is ShockWave Medical, Inc.?
ShockWave Medical, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be May 6, 2024. The company currently has a trailing EPS of 3.84.
Company Profile
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Community Discussion